ArticleInternational journal of particle therapy2026
Treatment Outcomes of Radiation Therapy of Paragangliomas of the Head and Neck at a Single Institution.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Stereotactic radiosurgery and photon therapy for the locoregional management of head and neck paragangliomas (HNPGLs) have been shown to provide long-term tumor control and symptomatic relief. We report proton therapy (PT) outcomes for HNPGLs at a single institution and describe stereotactic radiosurgery (SRS) and intensity-modulated radiation therapy (IMRT) outcomes as institutional context for modality selection. The primary goal is to report outcomes including tumor control, toxicity, and overall recovery, while evaluating differences across radiation modalities. Materials/Methods: This is a retrospective review of 52 adult patients with 54 non-metastatic HNPGLs receiving radiation therapy in a single institution. There were 9 tumors treated with IMRT, 23 with SRS, and 22 with PT. Median dose was 45 Gy (cobalt Gray equivalent [CGE]). Results: Out of 52 patients (14 male, 38 female) with a current median age of 65 (range 27-93), there were 30 jugular paragangliomas (PGLs), 1 tympanic PGL, 8 jugulotympanic PGLs, 3 vagal PGLs, 11 carotid body tumors, and 1 spinal PGL. The median age at the start of treatment was 59.5 years (range 18-85). Median follow-up was 50.3 months (range 3.6-147.2 months), with 52 (100%) patients alive at last follow-up. Local control, distant control, and overall survival were 98%, 100%, and 100%, respectively. No grade 3 to 5 toxicities were reported. At the end of follow-up, 53 (98%) tumors had a partial treatment response or were stable, and 20 (37%) experienced a decrease in volume. Of the 20 tumors that had a decrease in volume, 8 were treated with PT, 8 with SRS, and 4 with IMRT. PT was used more frequently for larger or anatomically complex tumors; SRS was preferred for small, well-circumscribed lesions; and IMRT was selected for moderate-sized or irregularly shaped tumors near critical structures before PT was available. Conclusion: PT was particularly useful in treating large or anatomically complex tumors, while SRS and IMRT offered strong outcomes for smaller or anatomically suitable lesions. We report favorable feasibility, local tumor control, survival, and toxicity of PT for HNPGLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.